Drugs / Pinocembrin
Pinocembrin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02059785 | Jun 2013 → Dec 2016 | ischemic stroke | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Suspended | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pinocembrin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02059785 ↗ |
| Known as | (2s)-pinocembrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL399910 ↗ |
| Known as | Dihydrochrysin | ChEMBL registry synonym — accepted as the source's own label CHEMBL399910 ↗ |
| Known as | Galangin flavanone | ChEMBL registry synonym — accepted as the source's own label CHEMBL399910 ↗ |
| Known as | NSC-279005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL399910 ↗ |
| Known as | NSC-43318 | ChEMBL registry synonym — accepted as the source's own label CHEMBL399910 ↗ |
| Modality | Small molecule | — CHEMBL399910 ↗ |
| Route | Intravenous | “40mg /60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day” NCT02059785 ↗ |